Breaking News Instant updates and real-time market news.

CMCSA

Comcast

$34.11

0.43 (1.28%)

, ABEO

Abeona Therapeutics

$10.60

0.565 (5.63%)

10:27
10/12/18
10/12
10:27
10/12/18
10:27

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Comcast (CMCSA) reinstated with an Overweight at JPMorgan. 2. Abeona Therapeutics (ABEO) initiated with a Buy at Mizuho. 3. Foamix (FOMX) initiated with an Overweight at Cantor Fitzgerald. 4. Match Group (MTCH) and IAC (IAC) were initiated with a Buy at Nomura Instinet while Angi Homeservices (ANGI) was initiated with a Neutral at Nomura Instinet. 5. Terex (TEX) initiated with a Neutral at Longbow. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

CMCSA

Comcast

$34.11

0.43 (1.28%)

ABEO

Abeona Therapeutics

$10.60

0.565 (5.63%)

FOMX

Foamix

$5.26

0.2 (3.95%)

MTCH

Match Group

$54.18

2.73 (5.31%)

IAC

IAC

$200.61

7.66 (3.97%)

ANGI

Angi Homeservices

$19.51

0.61 (3.23%)

TEX

Terex

$36.75

-0.58 (-1.55%)

CMCSA Comcast
$34.11

0.43 (1.28%)

10/12/18
JPMS
10/12/18
INITIATION
Target $42
JPMS
Overweight
Comcast reinstated with an Overweight at JPMorgan
JPMorgan analyst Philip Cusick reinstated coverage of Comcast with an Overweight rating and $42 price target following a period of restriction. The analyst says that while the Sky deal may position the company well long term, he doesn't "love it" due to the increased leverage and added complexity versus "what was previously a fairly simple story." However, Sky will account for just 9% of total company EBITDA and it may be too early to tell whether Comcast's foray into Europe will pan out at this point, Cusick tells investors in a research note. The analyst believes Comcast's current valuation is "compelling" given its top-line and EBITDA growth profile relative to mega cap peers.
10/03/18
STFL
10/03/18
NO CHANGE
Target $155
STFL
Buy
Trade Desk pullback due to misplaced concerns about Amazon, says Stifel
Stifel analyst John Egbert raised his mid- and long-term estimates for Trade Desk (TTD) citing momentum from new advertiser wins and the fact that platform spend and attach rates are benefiting from the recent New Wave product launch. He believes recent weakness in Trade Desk shares may be related to worries over online reports suggesting Amazon (AMZN) has discussed building a proprietary video ad serving product for its own streaming business, but sees these concerns as misplaced, Egbert added. Based on the available information, it seems like Amazon is focusing on video ad server technology, not a connected TV ad buying software tool, which would pit it against Trade Desk partners Comcast's (CMCSA) Freewheel and Google (GOOGL) Ad Manager, not Trade Desk itself, Egbert explains. He maintains a Buy rating on Trade Desk and raised his price target on the stock to $155 from $130.
09/26/18
KEYB
09/26/18
NO CHANGE
Target $43
KEYB
Overweight
Comcast price target raised to $43 from $38 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for Comcast ((CMCSA) to $43 from $38 as he sees a positive risk/reward. The analyst expects Comcast's cable business to outperform expectations, which should drive improved sentiment and profitability over the next one to two years. Nispel also believes there is an overhang lifted on the stock following its Sky (SKYAY) auction win. Comcast's management acumen to integrate Sky and the strategic value of the assets are underappreciated by Comcast investors, he contends, reiterating an Overweight rating on the shares.
09/25/18
JEFF
09/25/18
DOWNGRADE
JEFF
Hold
Sky downgraded to Hold from Buy at Jefferies
Jefferies analyst Jerry Dellis downgraded Sky (SKYAY) to Hold and lowered his price target for the shares to 1,728p from 1,750p. The analyst fully expects Comcast's offer to be accepted, allowing the acquisition to close by end-October.
ABEO Abeona Therapeutics
$10.60

0.565 (5.63%)

10/12/18
MZHO
10/12/18
INITIATION
Target $17
MZHO
Buy
Mizuho starts Abeona Therapeutics with Buy rating, $17 price target
Mizuho analyst Difei Yang last night initiated coverage of Abeona Therapeutics with a Buy rating and $17 price target. With two indications progressing towards phase 3 pivotal trials, Abeona is well positioned to address unmet needs in two rare diseases, Yang tells investors in a research note. She believes EB-101 for the treatment of recessive dystrophic epidermolysis bullosa has shown encouraging results in Phase 1/2 trials and that ABO-102 for the treatment of Sanfilippo syndrome Type A shows promise with early positive biomarker data.
10/11/18
MZHO
10/11/18
INITIATION
MZHO
Buy
Abeona Therapeutics initiated with a Buy at Mizuho
Mizuho analyst Difei Yang initiated Abeona Therapeutics with a Buy and $17 price target.
08/17/18
SBSH
08/17/18
NO CHANGE
SBSH
Buy
Start of Phase 3 trial for EB-101 an important catalyst for Abeona, says Citi
Following the premature publication of a draft protocol for Abeona Therapeutics' EB-101 trial by the company's collaborator, Citi analyst Liav Abraham said the start of this pivotal trial represents an important near-term catalyst for the stock. The analyst, who said that the Phase I/II trial for EB-101 in recessive dystrophic epidermolysis bullosa delivered "compelling data" on wound closure at 3 and 6-months, keeps a Buy rating on Abeona shares.
07/19/18
LTCO
07/19/18
NO CHANGE
Target $38
LTCO
Buy
Krystal Biotech price target raised to $38 from $23 at Ladenburg
Ladenburg analyst Wangzhi Li raised his price target for Krystal Biotech (KRYS) to $38 from $23, while reiterating a Buy rating on the shares. The analyst notes that KB103 Phase 1 data in dystrophic epidermolysis bullosa is on track for Q4 report with first patients being dosed for over 2 months now. This indicates good safety so far for the first patients dosed, he contends. As only 3-6 patients are expected to be needed for the whole Phase 1 trial, the analyst believes Krystal Biotech could potentially initiate a pivotal study in 1H 2019. Abeona (ABEO) expects to start a pivotal trial later this year for its autologous personalized ex vivo gene therapy for DEB, which could help establish the regulatory endpoint and pathway for DEB and KB103, Li adds.
FOMX Foamix
$5.26

0.2 (3.95%)

10/11/18
CANT
10/11/18
INITIATION
Target $15
CANT
Overweight
Foamix initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen initiated Foamix with an Overweight and $15 price target.
06/06/18
LEHM
06/06/18
DOWNGRADE
Target $8.5
LEHM
Equal Weight
Protagonist downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Protagonist Therapeutics to Equal Weight and lowered his price target for the shares to $8.50 from $30. The analyst continues to see value in the company's pipeline assets, but does expect achievement of key catalysts until the second half of 2019. As such, the analyst sees greater near-term potential in small cap names with catalysts upcoming, such as Foamix (FOMX).
09/12/18
HCWC
09/12/18
NO CHANGE
Target $14
HCWC
Buy
Foamix price target raised to $14 from $12 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Foamix Pharmaceuticals to $14 after the company announced that results of its third Phase 3 trial of FMX101 for moderate-to-severe acne met both co-primary endpoints. The analyst reiterates a Buy rating on the shares and expects a regulatory filing soon.
09/17/18
HCWC
09/17/18
NO CHANGE
Target $11
HCWC
Buy
Foamix price target lowered to $11 from $14 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Foamix Pharmaceuticals to $11 citing dilution from the recent equity financing. The analyst, who initially expected that Foamix would wait until at least after the topline results from the two pivotal FMX103 trials in rosacea to raise more capital, is encouraged "by the apparent healthy demand among investors for the shares." He keeps a Buy rating on Foamix.
MTCH Match Group
$54.18

2.73 (5.31%)

10/04/18
JEFF
10/04/18
NO CHANGE
Target $260
JEFF
Buy
IAC price target raised to $260 from $240 at Jefferies
Jefferies analyst Brent Thill raised his price target for IAC (IAC) to $260 in conjunction with his increased estimates for Match Group (MTCH). Trading at just 15 times 2019 EBITDA and a $5B market discount to its ownership in Match and Angi Homeservices (ANGI), IAC's valuation looks attractive at current share levels, Thill tells investors in a research note. The analyst says IAC remains a top mid-cap pick.
10/11/18
NOMU
10/11/18
INITIATION
Target $66
NOMU
Buy
Match Group initiated with a Buy at Nomura Instinet
Nomura analyst Mark Kelley initiated Match Group with a Buy and $66 price target.
10/11/18
NOMU
10/11/18
INITIATION
Target $246
NOMU
Buy
IAC initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Mark Kelley initiated IAC (IAC) with a Buy rating and a price target of $246, saying its shareholders should continue to benefit from the company's core "Liberty roots", strategic acquisitions, and spin-offs. The analyst notes that IAC can continue to create shareholder value based on the upside expected in Match Group (MTCH) of which it owns 81% and ANGI Homeservices (ANGI) of which it owns 87%.
10/11/18
NOMU
10/11/18
INITIATION
NOMU
Buy
Match Group initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Mark Kelley initiated Match Group (MTCH) with a Buy rating and $66 price target. Kelley sees Match remaining the clear leader in online dating, despite Tinder growth, the evolution of other brands such as OKCupid and PlentyOfFish, and Facebook's (FB) recent entry into dating -- which the analyst is not concerned about. Kelley estimates the global dating market, ex-China, will be $12B by 2020, and conservatively expects Match to comprise 20% of the market at that time.
IAC IAC
$200.61

7.66 (3.97%)

10/11/18
NOMU
10/11/18
INITIATION
Target $246
NOMU
Buy
IAC initiated with a Buy at Nomura Instinet
Nomura analyst Mark Kelley initiated IAC with a Buy and $246 price target.
10/11/18
BNCH
10/11/18
NO CHANGE
Target $260
BNCH
Buy
IAC price target raised to $260 from $204 at Benchmark
After recent meetings with the management team at Dotdash, Benchmark analyst Daniel Kurnos believes the company could "easily" be closing in on a $1B valuation on a standalone basis and remains an undervalued story within core IAC. The analyst, who sees Dotdash having meaningful runway in its multi-billion dollar total addressable market across its verticals while remaining profitable, raised his price target on IAC to $260 and keeps a Buy rating on the parent company's shares.
ANGI Angi Homeservices
$19.51

0.61 (3.23%)

10/10/18
WEDB
10/10/18
NO CHANGE
Target $26
WEDB
Outperform
Internal product executive as CEO successor improves Angi story, says Wedbush
Wedbush analyst Ygal Arounian notes that Angi Homeservices announced that Chief Product Officer Brandon Ridenour has been appointed CEO and will succeed Chris Terrill by year-end. The analyst believes the CEO succession paves the way for continued category leadership, product innovation and continuing to successfully leverage the combination of Homeadvisor and Angie's List. Arounian is positive on the succession and the pick of an internal product executive veteran, which shows the intent focus on a product-driven future. He reiterates an Outperform rating and $26 price target on the shares.
10/11/18
NOMU
10/11/18
INITIATION
Target $20
NOMU
Neutral
Angi Homeservices initiated with a Neutral at Nomura Instinet
Nomura Instinet started Angi Homeservices with a Neutral rating and $20 price target.
10/11/18
NOMU
10/11/18
INITIATION
Target $20
NOMU
Neutral
Angi Homeservices initiated with a Neutral on valuation at Nomura Instinet
Nomura Instinet analyst Mark Kelley initiated coverage of Angi Homeservices with a Neutral rating and $20 price target. The analyst finds the stock appropriately priced given his expectation for EBITDA growth over the next few years, paired with the company's margin profile relative to peers. He says he could look to become more positive on a pullback. However, Kelly estimates the size of the home services market at more than $800B by 2020, which he feels positions Angi for continued demand growth
TEX Terex
$36.75

-0.58 (-1.55%)

08/20/18
08/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Positive from Neutral at Susquehanna and to Overweight from Neutral at Piper Jaffray. 2. Qualcomm (QCOM) upgraded to Buy from Neutral at Rosenblatt with analyst Jun Zhang citing benefits from 5G smartphone growth over the next few years. 3. Flir Systems (FLIR) upgraded to Outperform from Market Perform at William Blair with analyst Louie DiPalma he believes, in the near-term, Flir's enhanced automation and software capabilities are rendering its sensors more powerful and driving adoption. Additionally, DiPalma believes thermal sensors will be common in autonomous vehicles over the longer term, which could be a major source of long-term upside. 4. RBS (RBS) upgraded to Buy from Neutral at Citi. 5. Terex (TEX) upgraded to Neutral from Underperform at Baird with analyst Mig Dobre citing its recent pullback and multiple compression as well as its upcoming investors day. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/22/18
UBSW
08/22/18
NO CHANGE
Target $52
UBSW
Buy
Terex sees continued growth in AWP market, says UBS
UBS analyst Steven Fisher met with Terex management who reiterated they are confident in demand growth from 2018-2023 and that they will get their share of the rising market. The analyst noted bears believe the AWP market is set to peak and rollover, but management expects industry revenues to grow at an upper single digit through 2023. Fisher reiterated his Buy rating and $52 price target on Terex shares.
09/05/18
DBAB
09/05/18
INITIATION
Target $34
DBAB
Sell
Terex resmed with a Sell at Deutsche Bank
Deutsche Bank analyst Chad Dillard resumed coverage of Terex with a Sell rating and $34 price target. Since late cycle concerns took hold in April, the Machinery sector has underperformed the S&P 500 by 15% and is approaching valuation lows last seen during the 2015 energy and 2008 global financial crises, Dillard tells investors in a research note. He resumed coverage of eight stocks in the Machinery sector, with two Buy ratings, one Sell rating and five Holds.
10/12/18
LBOW
10/12/18
INITIATION
LBOW
Neutral
Terex initiated with a Neutral at Longbow

TODAY'S FREE FLY STORIES

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

FN

Fabrinet

$55.23

0.67 (1.23%)

17:25
02/15/19
02/15
17:25
02/15/19
17:25
Hot Stocks
Fabrinet CFO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

UBER

Uber

$0.00

(0.00%)

17:24
02/15/19
02/15
17:24
02/15/19
17:24
Periodicals
Uber sues NYC over move to cap number of ride-hailing drivers, Bloomberg says »

Uber is suing New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

17:19
02/15/19
02/15
17:19
02/15/19
17:19
Periodicals
House Democrats to probe POTUS emergency declaration, Bloomberg says »

The House Judiciary…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$51.71

0.25 (0.49%)

17:11
02/15/19
02/15
17:11
02/15/19
17:11
Hot Stocks
Oracle authorizes additional $12B stock buyback under existing program »

In a regulatory 8K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

SBLK

Star Bulk Carriers

$8.21

0.13 (1.61%)

17:03
02/15/19
02/15
17:03
02/15/19
17:03
Hot Stocks
Star Bulk Carriers acquires 95,605 of its common shares »

Star Bulk Carriers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLI

Hollysys

$20.56

0.26 (1.28%)

17:02
02/15/19
02/15
17:02
02/15/19
17:02
Earnings
Hollysys reports Q2 adjusted EPS 73c, consensus 59c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

AKS

AK Steel

$2.98

-0.015 (-0.50%)

16:58
02/15/19
02/15
16:58
02/15/19
16:58
Syndicate
Breaking Syndicate news story on AK Steel »

AK Steel files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
02/15/19
02/15
16:55
02/15/19
16:55
General news
Treasury Market Summary: i »

Treasury Market Summary:…

LPTX

Leap Therapeutics

$1.65

(0.00%)

16:53
02/15/19
02/15
16:53
02/15/19
16:53
Hot Stocks
Valence Helix Investments discloses 10.99% stake in Leap Therapeutics »

Valence Helix disclosed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$23.25

-0.24 (-1.02%)

16:52
02/15/19
02/15
16:52
02/15/19
16:52
Hot Stocks
Mid Penn Bancorp seeks approval to relocate Allentown Boulevard branch »

Mid Penn Bank, subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$423.79

8.54 (2.06%)

, AMGN

Amgen

$188.31

1.6 (0.86%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
Regeneron says EPO revokes Immunex's European patent No. 2,990,420 »

Regeneron…

REGN

Regeneron

$423.79

8.54 (2.06%)

AMGN

Amgen

$188.31

1.6 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 28

    Apr

  • 13

    May

UPS

UPS

$110.89

-0.91 (-0.81%)

16:44
02/15/19
02/15
16:44
02/15/19
16:44
Hot Stocks
UPS CFO sells 9.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DAL

Delta Air Lines

$51.09

0.58 (1.15%)

16:43
02/15/19
02/15
16:43
02/15/19
16:43
Syndicate
Breaking Syndicate news story on Delta Air Lines »

Delta Air Lines files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$110.89

-0.91 (-0.81%)

16:42
02/15/19
02/15
16:42
02/15/19
16:42
Hot Stocks
UPS raises quarterly dividend to 96c per share from 91c »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.